Tempest Therapeutics, Inc. 8-K

What Happened
Tempest Therapeutics, Inc. (TPST) filed an 8-K on February 25, 2026 announcing interim results from the ongoing REDEEM-1 clinical trial of TPST-2003 and that it is preparing for a potential U.S. registrational study in 2026. The company also posted an updated corporate presentation (dated February 25, 2026) on the Investors → News, Events & Presentations section of its website. A press release titled “Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026” was issued the same day and is attached to the filing as Exhibit 99.1.

Key Details

• Updated corporate presentation dated February 25, 2026 posted to www.tempesttx.com (Investors → News, Events & Presentations).
• Press release issued February 25, 2026 announcing interim REDEEM-1 results and plans to prepare for a potential U.S. registrational study in 2026.
• The 8-K (filed 02/25/2026) includes the press release as Exhibit 99.1.

Why It Matters
Interim clinical data and a stated plan to prepare for a U.S. registrational study are material milestones for a biotech company — they can affect development timelines, regulatory strategy, and investor expectations for future value-driving catalysts. The updated corporate presentation and press release give investors the company’s current clinical status and next steps; for specific efficacy, safety, or enrollment details, investors should review the attached press release and presentation.